CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
1. Yalçin B, Kremer LC, van Dalen EC. High-dose chemotherapy and
autologous haematopoietic stem cell rescue for children with high-risk
neuroblastoma. Cochrane Database Syst Rev. 2015:CD006301.
2. Park JR, Kreissman SG, London WB, et al. Effect of Tandem Autologous
Stem Cell Transplant vs Single Transplant on Event-Free Survival in
Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
JAMA. 2019;322:746-755.
3. Ladenstein R, Pötschger U, Pearson ADJ, et al. Busulfan and melphalan
versus carboplatin, etoposide, and melphalan as high-dose chemotherapy
for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international,
randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol.
2017;18:500-514.
4. Kushner BH, Kramer K, Modak S, et al. Topotecan, thiotepa, and
carboplatin for neuroblastoma: failure to prevent relapse in the central
nervous system. Bone Marrow Transplant. 2006;37:271-276.
5. Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk
neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue:
results of the Chicago Pilot II Study. J Clin Oncol. 2002;20:2284-2292.
6. Sung KW, Son MH, Lee SH, et al. Tandem high-dose chemotherapy and
autologous stem cell transplantation in patients with high-risk
neuroblastoma: results of SMC NB-2004 study. Bone Marrow Transplant.
2013;48:68-73.
7. Seif AE, Naranjo A, Baker DL, et al. A pilot study of tandem
high-dose chemotherapy with stem cell rescue as consolidation for
high-risk neuroblastoma: Children’s Oncology Group study ANBL00P1. Bone
Marrow Transplant. 2013;48:947-952.
8. Hara J, Osugi Y, Ohta H, et al. Double-conditioning regimens
consisting of thiotepa, melphalan and busulfan with stem cell rescue for
the treatment of pediatric solid tumors. Bone Marrow Transplant.
1998;22:7-12.
9. Okada K, Yamasaki K, Nitani C, Fujisaki H, Osugi Y, Hara J.
Double-conditioning regimen consisting of high-dose thiotepa and
melphalan with autologous stem cell rescue for high-risk pediatric solid
tumors: A second report. Pediatr Blood Cancer. 2019;66:e27953.
10. Yamasaki K, Okada K, Soejima T, Sakamoto H, Hara J. Strategy to
minimize radiation burden in infants and high-risk medulloblastoma using
intrathecal methotrexate and high-dose chemotherapy: A prospective
registry study in Japan. Pediatr Blood Cancer. 2020;67:e28012.
11. Hashii Y, Kusafuka T, Ohta H, et al. A case series of children with
high-risk metastatic neuroblastoma treated with a novel treatment
strategy consisting of postponed primary surgery until the end of
systemic chemotherapy including high-dose chemotherapy. Pediatr Hematol
Oncol 2008;25:439-450.
12. Yamasaki K, Nakano Y, Tanaka C, et al. Retrospective analysis of
high-risk neuroblastoma treated by cord blood transplantation following
reduced-intensity conditioning: a single center experience. Jpn J
Pediatr Hematol Oncol. 2016;53:1-7.
13. Cohn SL, Pearson AD, London WB, et al. The International
Neuroblastoma Risk Group (INRG) classification system: an INRG Task
Force report. J Clin Oncol. 2009;27:289-297.
14. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the
international criteria for neuroblastoma diagnosis, staging, and
response to treatment. J Clin Oncol. 1993;11:1466-1477.
15. Morgenstern DA, London WB, Stephens D, et al. Prognostic
significance of pattern and burden of metastatic disease in patients
with stage 4 neuroblastoma: A study from the International Neuroblastoma
Risk Group database. Eur J Cancer. 2016;65:1-10.
16. Hishiki T, Matsumoto K, Ohira M, et al. Results of a phase II trial
for high-risk neuroblastoma treatment protocol JN-H-07: a report from
the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG). Int J
Clin Oncol. 2018;23:965-973.
17. Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy
increases the survival rates in patients with stage 4 neuroblastoma with
MYCN amplification. J Pediatr Hematol Oncol. 2002;24:613-621.
18. Simon T, Längler A, Harnischmacher U, et al. Topotecan,
cyclophosphamide, and etoposide (TCE) in the treatment of high-risk
neuroblastoma. Results of a phase-II trial. J Cancer Res Clin Oncol.
2007;133:653-661.
19. Shichino H, Mugishima H, Matsumoto K, et al. A phase II study of
bold delayed local control strategy in children with high risk
neuroblastoma: Japan Neuroblastoma Study Group (JN-H-11) trial. Pediatr
Blood Cancer. 2016;63:Suppl 3 (abstract).
20. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the
liver following bone marrow transplantation. Transplantation.
1987;44:778-783.
21. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant
clinical trials network toxicity committee consensus summary: thrombotic
microangiopathy after hematopoietic stem cell transplantation. Biol
Blood Marrow Transplant. 2005;11:571-575.
22. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF,
interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med.
2010;363:1324-1334.
23. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with
autologous stem-cell rescue versus oral maintenance chemotherapy as
consolidation treatment in patients with high-risk neuroblastoma: a
randomised controlled trial. Lancet Oncol. 2005;6:649-658.
24. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for
children with high-risk neuroblastoma treated on a randomized trial of
myeloablative therapy followed by 13-cis-retinoic acid: a children’s
oncology group study. J Clin Oncol. 2009;27:1007-1013.
25. Morgenstern DA, Pötschger U, Moreno L, et al. Risk stratification of
high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN
study. Pediatr Blood Cancer. 2018;65:e27363.
26. Kushner BH, Modak S, Kramer K, et al. Striking dichotomy in outcome
of MYCN-amplified neuroblastoma in the contemporary era. Cancer.
2014;120:2050-2059.
27. Stein J, Cohen IJ, Goshen Y, Kapelushnik J, Gavriel H, Yaniv I.
Doble thiotepa-melphalan conditioning for autologous stem cell
transplantation in children and young adults: two transplants for the
price of one. Bone Marrow Transplant. 2005;35:Suppl 96 (abstract).
28. Kondo E, Ikeda T, Goto H, et al. Pharmacokinetics of thiotepa in
high-dose regimens for autologous hematopoietic stem cell transplant in
Japanese patients with pediatric tumors or adult lymphoma. Cancer
Chemother Pharmacol. 2019;84:849-860.